Log In
BCIQ
Print this Print this
 

VT-464

  Manage Alerts
Collapse Summary General Information
Company Innocrin Pharmaceuticals Inc.
DescriptionOnce-daily, oral non-steroidal dual androgen receptor antagonist and cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17; CYP17A) inhibitor
Molecular Target Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A) ; Androgen receptor
Mechanism of ActionAndrogen receptor antagonist; Cytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today